Compare · SLNO vs VANI
SLNO vs VANI
Side-by-side comparison of Soleno Therapeutics Inc. (SLNO) and Vivani Medical Inc. (VANI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SLNO and VANI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 24.3x VANI ($113.8M).
- Over the past year, SLNO is down 39.2% and VANI is down 16.8% - VANI leads by 22.4 points.
- VANI has been more active in the news (19 items in the past 4 weeks vs 1 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 0 for VANI).
- Company
- Soleno Therapeutics Inc.
- Vivani Medical Inc.
- Price
- $53.02+0.08%
- $1.31-2.96%
- Market cap
- $2.76B
- $113.8M
- 1M return
- +0.76%
- +9.17%
- 1Y return
- -39.20%
- -16.83%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2014
- News (4w)
- 1
- 19
- Recent ratings
- 12
- 0
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest SLNO
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest VANI
- Director Williams Gregg bought $999,999 worth of shares (793,650 units at $1.26) (SEC Form 4)
- Vivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
- Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
- Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream
- Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
- ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
- Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
- Vivani Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits